Aller au contenu principal
Accès ouvert déclaré 2025 article

Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers

2Citations signalées — pas une note de qualité
160Institutions déclarées
22Pays d’affiliation déclarés

Résumé fourni par la source

BACKGROUND: Lung adenocarcinoma (LUAD) in never-smokers is a major public health burden, especially among East Asian women. Polygenic risk scores (PRSs) are promising for risk stratification but are primarily developed in European-ancestry populations. We aimed to develop and validate single- and multi-ancestry PRSs for East Asian never-smokers to improve LUAD risk prediction. METHODS: PRSs were developed using genome-wide association study summary statistics from East Asian (8,002 cases; 20,782 controls) and European (2,058 cases; 5,575 controls) populations. Single-ancestry models included PRS-25, PRS-CT, and LDpred2; multi-ancestry models included LDpred2+PRS-EUR128, PRS-CSx, and CT-SLEB. Performance was evaluated in independent East Asian data from the Female Lung Cancer Consortium (FLCCA) and externally validated in the Nanjing Lung Cancer Cohort (NJLCC). We assessed predictive accuracy via AUC, with 10-year and (age 30-80) absolute risks estimates. RESULTS: The best multi-ancestry PRS, using East Asian and European data via CT-SLEB (clumping and thresholding, super learning, empirical Bayes), outperformed the best East Asian-only PRS (LDpred2; AUC = 0.629, 95% CI:0.618,0.641), achieving an AUC of 0.640 (95% CI : 0.629,0.653) and odds ratio of 1.71 (95% CI : 1.61,1.82) per SD increase. NJLCC Validation confirmed robust performance (AUC =0.649, 95% CI: 0.623, 0.676). The top 20% PRS group had a 3.92-fold higher LUAD risk than the bottom 20%. Further, the top 5% PRS group reached a 6.69% lifetime absolute risk. Notably, this group reached the average population 10-year LUAD risk at age 50 (0.42%) by age 41, nine years earlier. CONCLUSIONS: Multi-ancestry PRS approaches enhance LUAD risk stratification in East Asian never-smokers, with consistent external validation, suggesting future clinical utility.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers
Date Crossref
01/10/2025
Éditeur
Oxford University Press (OUP)
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

National Cancer InstituteDivision of Cancer Epidemiology and GeneticsJiangsu Cancer HospitalNanjing Medical UniversityUniversity of OxfordNational Cancer Research InstituteKyungpook National UniversityAichi Cancer CenterNational Health Research InstitutesTunghai UniversityLunenfeld-Tanenbaum Research InstituteSinai Health SystemTianjin Medical University Cancer Institute and HospitalNational Taiwan University HospitalTianjin Medical UniversityVanderbilt University Medical CenterChonnam National UniversitySeoul National University HospitalChonnam National University HospitalChonnam National University Hwasun HospitalKorea UniversityAmerican Cancer SocietyChinese Academy of Medical Sciences & Peking Union Medical CollegeShenyang Medical CollegeChina Medical UniversityFirst Hospital of China Medical UniversityFudan UniversityPharmaceutical Biotechnology (Czechia)University of Hong KongNational University of SingaporeNational University Health SystemNational Dong Hwa UniversitySeoul National UniversityNew Generation University CollegeGuangdong Academy of Medical SciencesQueen Mary HospitalUniversity of North Carolina at Chapel HillGeorgetown UniversityGeorgetown University Medical CenterSt. Jude Children's Research HospitalInova Health SystemSejong UniversityKorea Research Institute of Bioscience and BiotechnologyNational Heart, Lung, and Blood InstituteShanghai Pulmonary HospitalNational Cancer CenterTokyo National HospitalHuazhong University of Science and TechnologyShiga University of Medical ScienceUniversity of Tokyo HospitalRIKEN Center for Integrative Medical SciencesThe University of TokyoTokyo Medical and Dental UniversityInstitute of Science Tokyo HospitalAlbert Einstein College of MedicineJapanese Red Cross Medical CenterKanagawa Prefectural Hospital OrganizationKanagawa Cancer CenterNational Cancer Center Hospital EastAkita UniversitySaga UniversityNagoya UniversityNippon Medical SchoolShinshu UniversityFukushima Medical UniversityFukushima Medical University HospitalGunma University HospitalGunma UniversityChina National Environmental Monitoring CenterNational Chung Hsing UniversityTaichung Veterans General HospitalChung Shan Medical University HospitalXiamen Chang Gung HospitalChung Shan Medical UniversityNational Cheng Kung University HospitalNational Yang Ming Chiao Tung UniversityTaipei Veterans General HospitalKyungpook National University Medical CenterShanghai Jiao Tong UniversityRenji HospitalLeidos (United States)Shandong Tumor HospitalShandong First Medical UniversityGenome Institute of SingaporeWayne State UniversityThe Barbara Ann Karmanos Cancer InstituteInstitute of Cancer ResearchCancer Genetics (United States)Houston Institute for Clinical ResearchCommunication University of ZhejiangZhejiang UniversityMayo Clinic in ArizonaBC Cancer AgencyLaboratoire d’immunologie intégrative du cancerUniversidad de OviedoCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South AfricaUniversity of TaipeiGenomics Research Center, Academia SinicaFred Hutch Cancer CenterAcademia SinicaUniversity of CopenhagenGentofte HospitalWorld Health OrganizationCentre international de recherche sur le cancerGerman Cancer Research CenterUniversity of SalzburgHeidelberg UniversityGerman Center for Lung ResearchNephrologisches Zentrum GoettingenZimmer Biomet (Netherlands)Helmholtz MunichZimmer Biomet (Germany)Ludwig-Maximilians-Universität MünchenMassachusetts Department of Public HealthHarvard UniversityTechnion – Israel Institute of TechnologyMarkey Cancer CenterUniversity of LiverpoolThe University of Texas MD Anderson Cancer CenterUniversity of Hawaiʻi at MānoaUniversity of Hawaii SystemCancer Center of HawaiiUniversity of Hawaii Cancer CenterPrincess Margaret Cancer CentreCotton (United States)USC Norris Comprehensive Cancer CenterRadboud University NijmegenRadboud University Medical CenterNational Institute of Occupational HealthUmeå UniversityUniversity of SheffieldUPMC Hillman Cancer CenterUniversity of Pittsburgh Medical CenterUniversity at Buffalo, State University of New YorkMoffitt Cancer CenterFrederick National Laboratory for Cancer ResearchLeidos Biomedical Research Inc. (United States)University of California, San FranciscoUniversity of California SystemKorea UniversitySeoul National University Bundang HospitalCancer Research InstituteTaipei Medical UniversityLiaoning Cancer Hospital & InstituteNational Hsinchu University of EducationCastle Peak HospitalGleneagles HospitalUtrecht UniversityShanghai Medical College of Fudan UniversityZhongshan HospitalQueen Elizabeth HospitalQujing Normal UniversityCenter for Global HealthResearch Center for Applied Science, Academia SinicaInstitute of Sociology, Academia SinicaJohns Hopkins UniversityJohns Hopkins MedicineBaylor College of MedicineChildren's Cancer CenterNew Mexico Cancer Center

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Genetic Associations and EpidemiologyFerroptosis and cancer prognosisLung Cancer Treatments and Mutations

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.